Emphysema Treatment Guidelines

Emphysema Treatment Guidelines

Emphysema treatment guidelines usually focus on reducing a patient’s symptoms and improving his or her quality of life. Recommendations may vary from person to person, although a combination of medications, lifestyle changes and supplemental therapies is fairly common.

Depending on a person’s age, medical history, diagnosis and symptoms, his or her emphysema treatment guidelines may include:

  • Short- or long-acting bronchodilators (medications that help open the airways)
  • Corticosteroids (medications that help reduce inflammation)
  • Antibiotics (medications that can help prevent infections during severe flare-ups)
  • Expectorants (medications that help dissolve mucus and alleviate the urge the cough)
  • A smoking cessation program (if applicable)
  • Oxygen therapy
  • Vaccinations to prevent the flu and pneumococcal pneumonia
  • Surgery to remove air-filled lesions from the lungs, remove severely damaged lung tissue or compensate for a loss of elasticity by blocking air from entering a compartment of the lungs
  • Lung transplant surgery (for severe, end-stage emphysema)

Some people also choose to explore alternative treatments for emphysema. One such option is cellular therapy, in which a person’s own cells are used to promote the body’s natural healing process. This treatment – unlike others, which can only help lessen symptoms – has the unique potential to help reduce inflammation and possibly even slow the progression of the disease. However, it is best used as part of a comprehensive treatment plan, helping to enhance the effects of traditional treatments.

If you’ve explored some or all of the emphysema treatment options that are commonly recommended by clinical guidelines but haven’t achieved the results you need, the Lung Institute can help you determine if cellular therapy may be able to help you breathe easier. To learn more about our alternative emphysema treatment options, contact us today at (800) 729-3065.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.